Stay updated with the latest
news from Antag Therapeutics
Antag Therapeutics expands senior team to support clinical progress
Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new hires to support the Company’s next phase of growth following the recent initiation of a Phase 1 trial of...
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, pharmacokinetics, and metabolic effects in healthy lean subjects and subjects living with obesity With strong genetic and...
Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics
Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma Pivotal time of transition as the company prepares to start clinical development of its first in-class lead candidate, AT-7687 in obesity AT-7687 offers a...
Antag Therapeutics Announces €80 Million Series A Financing
Round led by Versant Ventures with participation from founding investor Novo Holdings and new investors SR One, Dawn Biopharma and Pictet Entering Phase I testing for next-generation weight loss therapy by antagonizing GIPR Antag Therapeutics, a next-generation...
Antag Therapeutics Announces FDA Clearance ofInvestigational New Drug (IND) Application for LeadMolecule, AT-7687
Antag Therapeutics, a leading biopharmaceutical company focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneer novel treatments for obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors
Brings substantial industry expertise and strategic focus for sustained company development Antag Therapeutics ApS, a privately-held biotechnology company focused on the development of novel treatments for dietary-related diseases with obesity as its prime focus,...